C4 Therapeutics, Inc.
CCCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$105,316 | -$132,493 | -$128,175 | -$83,892 |
| Dep. & Amort. | $1,818 | $1,880 | $1,676 | $1,492 |
| Deferred Tax | $0 | $0 | $0 | $1,879 |
| Stock-Based Comp. | $29,662 | $27,235 | $30,016 | $21,512 |
| Change in WC | $7,648 | -$6,938 | -$16,779 | -$30,090 |
| Other Non-Cash | $1,031 | $3,478 | $7,323 | $2,134 |
| Operating Cash Flow | -$65,157 | -$106,838 | -$105,939 | -$86,965 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$180 | -$1,708 | -$5,496 | -$1,277 |
| Net Acquisitions | $0 | $0 | -$63,918 | $188,059 |
| Inv. Purchases | -$284,321 | -$129,898 | -$219,527 | -$537,740 |
| Inv. Sales/Matur. | $233,231 | $289,955 | $283,445 | $349,681 |
| Other Inv. Act. | $0 | $0 | $63,918 | -$188,059 |
| Investing Cash Flow | -$51,270 | $158,349 | $58,422 | -$189,336 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$12,500 | $0 | $0 |
| Stock Issued | $44,370 | $57,673 | $777 | $169,465 |
| Stock Repurch. | -$194 | -$110 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $1,160 | $426 | $370 | $1,935 |
| Financing Cash Flow | $45,336 | $45,489 | $1,147 | $171,400 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$71,091 | $97,000 | -$46,370 | -$104,901 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $130,033 | $33,033 | $79,403 | $184,304 |
| End Cash | $58,942 | $130,033 | $33,033 | $79,403 |
| Free Cash Flow | -$65,337 | -$108,546 | -$111,435 | -$88,242 |